Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.

Participated · Series B · Jul 2024

博瑞迪 provides low-cost genotyping and targeted gene capture sequencing solutions focused on molecular breeding for plants and animals. The company owns two proprietary targeted capture technology systems, GenoPlexs and GenoBaits. Its technology emphasizes high capture efficiency, flexible marker and capture types, and low-cost customized services for customers. The article reports that 博瑞迪 completed a RMB 250 million Series B financing. Participating investors and deal advisors are listed in the financing announcement. The article does not disclose operating metrics, founding year, or detailed future plans. Boruidi Bio builds a fully domestic, closed‑loop molecular breeding detection platform spanning database, algorithms, reagents and automated testing equipment, anchored on its proprietary liquid‑phase capture sequencing and GBTS technical system. The company positions itself as a third‑party service platform providing standardized sampling, high‑throughput detection and bioinformatics to breeding enterprises, and reports enabling customers to shorten breeding cycles by >50%, raise selection accuracy by 20–30%, and cut costs by over 90%. Boruidi says it has supported nearly 300 breeding units across more than 60 species and amassed roughly 2.5 PB of genetic data and ~800 billion variant data points. The team is led by founder Zhang Jia‑nan and includes members with experience from BGI, 23mofang, Wageningen, Cornell and other institutions. Recent plans include continued R&D and iterative upgrades, construction of a gene‑editing platform, and domestic and overseas business expansion. Financially the company has completed multiple financings in the past 18 months totaling over ¥100M, and will use new proceeds to accelerate technology development and market expansion.

Participated · Equity · Nov 2023

Bang'er Orthopedics is a leading chain of orthopedic specialty hospitals in China with more than 20 years of experience. It controls and operates 17 medical institutions across five provinces and 16 cities, including 16 secondary or tertiary-standard hospitals and one internet hospital. The group can open over 5,000 total beds and performs more than 40,000 surgeries annually. Its hospitals specialize in trauma orthopedics, spine, joint, sports medicine, hand and foot microsurgery, non-surgical treatment of neck/shoulder/lumbar/leg pain, traditional Chinese orthopedics, and rehabilitation. Over half of its hospitals are equipped with domestic and international orthopedic surgical robots and the group is an initial member of Beijing Jishuitan Hospital's national 5G+ orthopedic robot alliance, applying digital technologies across multiple clinical areas. The company plans to use the new funding to accelerate digital orthopedic construction, expand nationally, standardize operations, build specialist talent pipelines, and deepen cooperation with the insurance industry.

Led · Series B · Aug 2023

HC Scientific is described in the article as a Chinese life sciences firm. The company has secured 300 million yuan (about $41.2 million) in an extended Series B financing. The extension was reported as co-led by Lake Bleu Capital. Lake Bleu Capital is identified as a Hong Kong–based investor that specialises in healthcare investing primarily in the Greater China region. The article does not disclose HC Scientific’s specific core products, future plans, or operating metrics. No additional financial or operational details were provided in the article.

Participated · Series A · Jul 2023

CoJourney Inc. is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies, offering end-to-end services for plasmids, viral vectors, and mRNA. The company operates a 130,000 square foot state-of-the-art cGMP manufacturing facility equipped with 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Its proprietary technology platform and scalable processes support process development, cGMP production, analytical method development, QC testing and release, banking, drug substance production, and drug product filling. CoJourney employs over 150 scientific and operations staff and its management team has more than 15 years of operational experience in cell and gene therapy manufacturing globally. The company reports a track record of delivering high-quality genetic medicines and has manufactured products approved by global regulatory agencies, including the US FDA, for use in clinical trials. CoJourney is expanding its US operations and commercial manufacturing capabilities to expedite production and serve clients from early development through clinical and commercial-scale manufacturing.